In our earlier study, we tested whether quantifying CD8+ and CD163+ cells, individually and in combination, in both the tumor center (TC) and the invasive margin (IM) could refine immunoscoring in BCa and enhance conventional prognostic indicators [67]. The gene discussed is CD163; the disease is neoplasm.